By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MorphoSys AG 

Lena-Christ-Strasse 48

Martinsried  Munich  82152  Germany
Phone: 49-0-89-899-27-0 Fax: 49-0-89-899-27-222



Company News
MorphoSys AG Receives Clinical Milestone For Start Of Phase 1 Trial With Novel Cancer Antibody 10/21/2016 9:08:22 AM
MorphoSys AG Presents Updated Clinical Results For MOR202 At Medical Conference 10/17/2016 10:31:40 AM
MorphoSys AG Announces That Its Licensee Janssen R&D Reports Positive Results From A Phase 3 Study Of Guselkumab In Plaque Psoriasis 10/4/2016 8:48:22 AM
MorphoSys AG Moves Closer To Getting First Antibody Drug On Market 10/3/2016 6:44:32 AM
MorphoSys AG And Galapagos (GLPG.BR) Start First-In-Patient Dosing of IL-17C Antibody MOR106 In Atopic Dermatitis 9/29/2016 9:22:32 AM
MorphoSys AG Appoints Four R&D Experts To Its Newly Formed Scientific Advisory Board 9/12/2016 6:42:59 AM
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016 2:28:12 PM
MorphoSys AG Successfully Completes Safety Run-in Of MOR208 In L-MIND Combination Study In Patients With DLBCL 8/3/2016 9:12:12 AM
MorphoSys AG Reports Results For The First Six Months Of 2016 8/1/2016 9:37:31 AM
MorphoSys AG To Host Q2 2016 Conference Call On August 1, 2016 7/25/2016 9:41:24 AM